We are thrilled to announce that we have advanced to the Phase 2 accelerator in the #LymeXDiagnosticsPrize. Learn more:
- February 7, 2023
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
© 2022 T2 Biosystems, Inc.
We are thrilled to announce that we have advanced to the Phase 2 accelerator in the #LymeXDiagnosticsPrize. Learn more:
A recent systematic review and meta-analysis published in @TheLancet found that roughly 60% of bacterial co-infections or secondary infections in #COVID19 patients were resistant to antimicrobials.
Please tell us where you are visiting from: United States | Outside the United States